Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects.

European journal of clinical pharmacology - 1 Feb 2003

Ohara Koichi, Tanabu Shigeru, Ishibashi Kazuhisa, Ikemoto Keiko, Yoshida Kimiko, Shibuya Haruo

Abstract excerpt

OBJECTIVE: The purpose of the present study was to investigate whether plasma fluvoxamine (FV) concentration is associated with CYP2D6*10 allele polymorphisms. METHODS: Subjects were 46 Japanese patients (21 males) carrying neither *3, *4 nor *5 alleles and treated orally using FV. Venous blood was obtained from each patient for determination of FV concentration/dose (C/D) ratio (plasma concentration of FV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Alleles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Dose-Response Relationship, Drug

Share to Fluvoxamine

Share to Polymorphism, Genetic

Share to Selective Serotonin Reuptake Inhibitors

Source

Identifiers

PMID: 12610741
DOI: 10.1007/s00228-002-0529-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects.PMID 12610741Read ↗

Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration.Semantic proximity Read ↗

Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients.Semantic proximity Read ↗

CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics.Semantic proximity Read ↗

Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.Semantic proximity Read ↗

Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.Semantic proximity Read ↗

Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression.Semantic proximity Read ↗

Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder.Semantic proximity Read ↗

Polymorphisms in the 5-Hydroxytryptamine 2A Receptor and CytochromeP4502D6 Genes Synergistically Predict Fluvoxamine-Induced Side Effects in Japanese Depressed PatientsSemantic proximity Read ↗

Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.Semantic proximity Read ↗

The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population.Semantic proximity Read ↗

Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.Semantic proximity Read ↗

Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.